dc.contributor.author | Neophytou, Christiana M. | en |
dc.contributor.author | Constantinou, Andreas I. | en |
dc.creator | Neophytou, Christiana M. | en |
dc.creator | Constantinou, Andreas I. | en |
dc.date.accessioned | 2019-11-04T12:52:24Z | |
dc.date.available | 2019-11-04T12:52:24Z | |
dc.date.issued | 2015 | |
dc.identifier.issn | 2314-6133 | |
dc.identifier.uri | http://gnosis.library.ucy.ac.cy/handle/7/53270 | |
dc.description.abstract | Vitamin E isoforms have been extensively studied for their anticancer properties. Novel drug delivery systems (DDS) that include liposomes, nanoparticles, and micelles are actively being developed to improve Vitamin E delivery. Furthermore, several drug delivery systems that incorporate Vitamin E isoforms have been synthesized in order to increase the bioavailability of chemotherapeutic agents or to provide a synergistic effect. D-alpha-tocopheryl polyethylene glycol succinate (Vitamin E TPGS or TPGS) is a synthetic derivative of natural alpha-tocopherol which is gaining increasing interest in the development of drug delivery systems and has also shown promising anticancer effect as a single agent. This review provides a summary of the properties and anticancer effects of the most potent Vitamin E isoforms and an overview of the various formulations developed to improve their efficacy, with an emphasis on the use of TPGS in drug delivery approaches. © 2015 Christiana M. Neophytou and Andreas I. Constantinou. | en |
dc.source | BioMed Research International | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84934932682&doi=10.1155%2f2015%2f584862&partnerID=40&md5=83a028253ab60f7cca03d8fc34b40aee | |
dc.subject | Review | en |
dc.subject | antineoplastic agent | en |
dc.subject | Antineoplastic Agents | en |
dc.subject | human | en |
dc.subject | Neoplasms | en |
dc.subject | Humans | en |
dc.subject | drug effect | en |
dc.subject | drug efficacy | en |
dc.subject | antineoplastic activity | en |
dc.subject | nonhuman | en |
dc.subject | pathology | en |
dc.subject | drug mechanism | en |
dc.subject | drug potentiation | en |
dc.subject | liposome | en |
dc.subject | Liposomes | en |
dc.subject | macrogol | en |
dc.subject | clinical evaluation | en |
dc.subject | chemistry | en |
dc.subject | drug bioavailability | en |
dc.subject | drug metabolism | en |
dc.subject | drug formulation | en |
dc.subject | drug delivery system | en |
dc.subject | Drug Delivery Systems | en |
dc.subject | analogs and derivatives | en |
dc.subject | drug distribution | en |
dc.subject | structure analysis | en |
dc.subject | nanoparticle | en |
dc.subject | Nanoparticles | en |
dc.subject | tumor cell line | en |
dc.subject | micelle | en |
dc.subject | physical chemistry | en |
dc.subject | intracellular transport | en |
dc.subject | Cell Line, Tumor | en |
dc.subject | alpha tocopherol | en |
dc.subject | Vitamin E | en |
dc.subject | alpha tocotrienol | en |
dc.subject | tocofersolan | en |
dc.subject | drug potency | en |
dc.subject | drug structure | en |
dc.subject | alpha-Tocopherol | en |
dc.subject | biological activity | en |
dc.subject | drug industry | en |
dc.subject | effective concentration | en |
dc.subject | nanoencapsulation | en |
dc.subject | succinic acid | en |
dc.title | Drug delivery innovations for enhancing the anticancer potential of vitamin e isoforms and their derivatives | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1155/2015/584862 | |
dc.description.volume | 2015 | |
dc.author.faculty | Σχολή Θετικών και Εφαρμοσμένων Επιστημών / Faculty of Pure and Applied Sciences | |
dc.author.department | Τμήμα Βιολογικών Επιστημών / Department of Biological Sciences | |
dc.type.uhtype | Article | en |
dc.description.notes | <p>Cited By :9</p> | en |
dc.source.abbreviation | BioMed Res.Int. | en |
dc.contributor.orcid | Constantinou, Andreas I. [0000-0003-0365-1821] | |
dc.gnosis.orcid | 0000-0003-0365-1821 | |